Home » Stocks » Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd. (CHGCY)

Stock Price: $22.76 USD -0.16 (-0.70%)
Updated Aug 7, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 18.71B
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 3.29B
EPS (ttm) 2.85
PE Ratio 7.99
Forward PE 34.48
Dividend $0.29
Dividend Yield 1.27%

Stock Quote

Trading Day Aug 7, 2020
Last Price $22.76
Previous Close $22.92
Change ($) -0.16
Change (%) -0.70%
Day's Open 22.59
Day's Range 22.59 - 22.79
Day's Volume 28,477
52-Week Range 11.32 - 100.00

More Stats

Market Cap 18.71B
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date Jul 6, 2020
Shares Outstanding 3.29B
Float 1.27B
EPS (basic) n/a
EPS (diluted) 2.85
FCF / Share n/a
Dividend $0.29
Dividend Yield 1.27%
Earnings Yield 12.52%
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta 0.70
PE Ratio 7.99
Forward PE 34.48
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 8.78
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share 0.00
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA 15.55%
ROE 22.45%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

*No analysts have provided price targets for this stock.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Chugai Pharmaceutical Co., Ltd.
Country Japan
Employees 7,394
CEO Tatsuro Kosaka

Stock Information

Ticker Symbol CHGCY
Stock Exchange US OTC
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier OTCMKTS: CHGCY


Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, marketing, and distribution of prescription medicines in Japan and internationally. The company's products for oncology primarily include Avastin, Herceptin, Rituxan, Alecensa, Perjeta, Xeloda, Tarceva, Kadcyla, Zelboraf, Neutrogin, Tecentriq, and Gazyva; bone and joint diseases/autoimmune diseases comprise Actemra, Edirol, Suvenyl, and Bonviva; renal diseases consist of Mircera and Oxarol; and other diseases comprise Tamiflu, CellCept, Copegus, and Hemlibra. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group and Genentech; and co-development agreements with Taisho Pharmaceutical Co., Ltd. and Nippon Shinyaku Co., Ltd. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.